Further, to understand the role of YAP/TAZ in PFKFB3 mediated regression of cancer stemness and ABCG2 expression, XMU-MP-1 (an inhibitor that activates YAP/TAZ via MST1/2 inhibition [37]) used to activate YAP/TAZ in H1048CSC and H1882CSC cells and when treated with PFK158. Here, PFKFB3 is linked to cancer.